Atara biotherapeutics reports inducement grants under nasdaq listing rule 5635(c)(4)

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic ebv t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 126,928 restricted stock units of atara's common stock to four newly hired employees and stock options to purchase an aggregate of 186,378 shares of atara's common stock to three such newly hir
ATRA Ratings Summary
ATRA Quant Ranking